AAPL vs BIO Stock Comparison

AAPL currently leads BIO in this stock comparison, with AIQ scores of 74 vs 73. The clearest difference is quality, while BIO has the stronger value profile.

Market data as of Nov 18, 2026 market close· AIQ score gap 1 points
AAPL
Technology
vs
BIO
Healthcare
AAPL
Apple Inc.
Leads
Price
$352
Day move
+0.15%
AIQ Score
74/100
Best edge
Quality
Sector
Technology
BIO
Bio-Rad Laboratories, Inc.
Price
$370
Day move
+3.34%
AIQ Score
73/100
Best edge
Value
Sector
Healthcare

What is the main difference between AAPL and BIO?

AAPL leads the current stock comparison as Apple Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Apple Inc. vs Bio-Rad Laboratories, Inc.

Data as of Nov 18, 2026· market close· Cross-sector · Technology vs Healthcare· Coverage 62/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 2/10

AAPL leads

AAPL leads by 1 AIQ points, primarily on Quality and Risk Resilience.

Fragile: 2 of 5 evidence groups support AAPL, and its signal state is cleanly positive.

Evidence agreement: 2 of 5Comparison trend: Stable
AAPL

Apple Inc.

Leads
AIQ Score
74/100
AIQ Edge Score
10/10
BIO

Bio-Rad Laboratories, Inc.

AIQ Score
73/100
AIQ Edge Score
10/10

The Algovestiq AIQ Score currently favors AAPL over BIO, 74 versus 73 as of Nov 18, 2026. AAPL's advantage is driven primarily by stronger quality and risk resilience, while BIO holds the stronger value profile. AAPL also shows the stronger technical structure relative to its 50-day moving average. 2 of 5 covered evidence groups favor AAPL today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 1 points. AAPL lead: Stable — the AIQ differential has held near 1 points over 30 sessions.

Compare Apple Inc. and Bio-Rad Laboratories, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Total return with distributions reinvested, from daily closes.

AAPL
+124.2%
BIO
-51.1%

Total return comparison

Growth of $10,000, distributions reinvested

AAPL $22,424 · BIO $4,886

Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.

Compare AAPL and BIO against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

AAPL advantage
0
BIO advantage
  • Value56 vs 80
    BIO +24
  • Quality69 vs 61
    AAPL +8
  • Risk Resilience82 vs 74
    AAPL +8
  • Momentum84 vs 79
    AAPL +5

2 of 5 evidence groups favor AAPL. AAPL’s edge is concentrated in quality and risk resilience; BIO keeps a meaningful value edge.

What changed since the last close

Latest scored session 2026-11-18, compared against the prior scored session 2026-11-17.

AAPL+1 AIQ

Largest factor move: Momentum +1

No signal started or stopped since the prior session; its 7 active signals are unchanged.

BIO0 AIQ

Largest factor move: Momentum -1, not enough on its own to move the overall score.

New signals

  • MACD Bearish Crossover — bearish, momentum, short horizon
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon

AAPL's lead widened by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — AAPL and BIO both carry a full feed there.

The central trade-off

AAPL (Apple Inc.): the stronger current systematic profile, led by quality and risk resilience.

BIO (Bio-Rad Laboratories, Inc.): the counter-case, on value, valuation.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

AAPL

AAPL on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

BIO

BIO on combined revenue and EPS growth.

Value

BIO

BIO on the peer-relative Value factor, by 24 points.

Momentum

AAPL

AAPL on the Momentum factor, by 5 points.

Lower downside

AAPL

AAPL on Risk Resilience, by 8 points.

Analyst upside

Even

Analyst targets are level or not covered for both names.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureAAPLBIONote
Implied upside to target-0.3%—Level
Target dispersion+33.3%—Lower is tighter analyst agreement
ConsensusBuyHoldContext, not a primary driver
Analysts covering463Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

2 of 5 covered evidence groups favor AAPL. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreEven74 vs 73
FundamentalsEvenEPS growth 3.9% vs 23.3%; TTM ROE 27.4% vs 6%; gross margin 48.8% vs 51.3%; operating margin 33% vs 4.6%
ValuationBIOValue 56 vs 80
TechnicalsAAPLPrice vs 50-day 4% vs -0.7%; vs 200-day 18.3% vs 15.6%
Risk ResilienceAAPLRisk Resilience 82 vs 74
Analyst expectationsNot coveredNot covered

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of AAPL and BIO and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is narrow at 1 points. (argues the conclusion is provisional)
  • Only 2 of 5 covered evidence groups agree. (argues the conclusion is provisional)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader's signal state is cleanly positive. (supports the conclusion holding)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on AAPL.

How the comparison changed

120 daily snapshots · Jun 1 – Nov 18

AAPL lead: Stable — the AIQ differential has held near 1 points over 30 sessions.

Jun 1AAPL leads above the line · BIO leads belowNov 18
Today
AAPL +1
74 vs 73
7 sessions ago
BIO +1
74 vs 75
30 sessions ago
AAPL +1
73 vs 72
90 sessions ago
BIO +3
70 vs 73

The lead changed hands 3 times in this window, most recently on Oct 15 when AAPL moved ahead of BIO.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

AAPL

6 bullish / 0 bearish / 1 neutral

Only AAPL

  • Bollinger Band Squeeze — neutral, volatility, short horizon (6.9%)
  • 52-Week High Proximity — bullish, risk_regime, long horizon (0.0%)
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon
  • Uptrend Structure Active — bullish, trend, long horizon
BIOConflicted

3 bullish / 2 bearish / 1 neutral, conflicted

Only BIO

  • ATR Expansion - Breakout Mode — neutral, volatility, short horizon (3.56%)
  • MACD Bearish Crossover — bearish, momentum, short horizon
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon

Both carry 3 more signals that do not separate them: Golden Cross Active, EMA Ribbon Expansion Bullish, TRIX Bullish Signal.

BIO is conflicted, so the timing case there is weaker than the score alone suggests.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

AAPLConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +0.15%, AIQ +1 points).

BIONo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +3.34%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1BIO closes the Quality gap — currently 8 points behind, the largest single contributor to AAPL's edge.
  2. 2BIO's MACD Bearish Crossover resolves — a bearish momentum rule currently active against it.
  3. 3AAPL's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

Split
MetricAAPLBIO
Revenue growth (YoY)4.6%0.8%
EPS growth (YoY)3.9%23.3%
Gross margin48.8%51.3%
Operating margin33%4.6%
Return on equity (TTM)27.4%6%
Debt to equity0.710.18

Performance

AAPL leads 5 of 6 windows
MetricAAPLBIO
1 week (5 sessions)4.1%-4%
1 month (20 sessions)3.7%3.6%
3 months (63 sessions)16.6%3.1%
6 months (126 sessions)18.7%48%
Year to date31%20.9%
1 year (252 sessions)30.3%11.9%

Technicals

AAPL has the stronger structure
MetricAAPLBIO
RSI (14)60.645.4
ADX (14)18.712.9
Price vs 50-day4%-0.7%
Price vs 200-day18.3%15.6%
Volatility (1M, annualized)27.9%31.4%

Risk

AAPL is the more resilient
MetricAAPLBIO
Beta0.620.73
Sharpe ratio1.040.47
Sortino ratio1.520.69
Max drawdown-13.8%-27.2%
Current drawdown0%-6.1%
Annualized volatility24.9%36.2%
Value at risk (95%)-2%-3%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, AAPL or BIO?

On the Algovestiq AIQ Score, AAPL is the stronger of the two as of Nov 18, 2026, scoring 74 against BIO's 73. The edge comes from quality and risk resilience. BIO is not without a case — it holds the better value profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is AAPL or BIO the better buy right now?

AAPL carries the stronger systematic profile as of Nov 18, 2026, and the comparison is rated Fragile — 2 of 5 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 1 points. Treat the lead as provisional.

Why does the AIQ Score favor AAPL over BIO?

The composite weights Quality, Value, Momentum and Risk Resilience. BIO leads Value by 24 points; AAPL leads Quality by 8 points; AAPL leads Risk Resilience by 8 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, AAPL or BIO?

Analyst price targets imply -0.3% upside for AAPL and not covered for BIO. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, AAPL or BIO?

BIO is the better-valued of the two on the peer-relative Value factor. BIO on the peer-relative Value factor, by 24 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, AAPL or BIO?

BIO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, AAPL or BIO?

AAPL on the Momentum factor, by 5 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, AAPL or BIO?

AAPL is the more resilient of the two, so the other name carries the higher downside risk. AAPL on Risk Resilience, by 8 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is AAPL more profitable than BIO?

The profitability evidence is mixed: gross margin 48.8% vs 51.3%; operating margin 33% vs 4.6%; ttm roe 27.4% vs 6%. AAPL leads on two measures and BIO on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is AAPL's lead over BIO getting stronger or weaker?

AAPL lead: Stable — the AIQ differential has held near 1 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-01 and 2026-11-18. The lead has changed hands 3 times in that window, most recently on 2026-10-15, when AAPL moved ahead of BIO.

What would change the AAPL vs BIO verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: BIO closes the Quality gap — currently 8 points behind, the largest single contributor to AAPL's edge; BIO's MACD Bearish Crossover resolves — a bearish momentum rule currently active against it; AAPL's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about AAPL and BIO?

AAPL: 6 bullish / 0 bearish / 1 neutral. BIO: 3 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on AAPL is Golden Cross Active (bullish, long horizon). On BIO it is Golden Cross Active (bullish, long horizon).

Compare AAPL and BIO with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.